News Category
NanoViricides has received regulatory approval to start a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a mor...
As the Bundibugyo Ebola outbreak in the DRC escalates, GeoVax highlights its MVA-based vaccine candidates and expertise, positioning itself for potent...
NanoViricides' regulatory approval to trial its oral antiviral NV-387 for Ebola in the DRC may offer a more accessible treatment option in outbreak se...
NanoViricides has submitted an application to begin a Phase II trial of its NV-387 Oral Gummies for Bundibugyo ebolavirus in the DRC, where no approve...
NanoViricides has applied to launch a Phase II trial of its oral antiviral NV-387 for the Bundibugyo ebolavirus outbreak in the DRC, potentially offer...
NanoViricides announced ethics committee approval in the DRC for a Phase II trial of NV-387 oral gummies against Bundibugyo ebolavirus, positioning it...
Despite Middle East unrest disrupting key mining inputs, the Democratic Republic of Congo's copper and cobalt production remains unaffected, offering ...
NanoViricides (NYSE American: NNVC) progresses its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak i...
NanoViricides has shipped its broad-spectrum antiviral candidate NV-387 to the Democratic Republic of Congo for a Phase II clinical trial targeting MP...
NanoViricides announced approval from the Democratic Republic of Congo's Pillar Committee to proceed with a Phase II clinical trial of its oral antivi...
Redwood AI Corp. has signed a letter of intent with Dr. Placide Sesonga to develop an AI-driven pathogen tracking and outbreak intelligence initiative...
Trident Digital Tech Holdings Ltd. (NASDAQ: TDTH) announced the launch of TDTHAI, an AI platform for enterprises and governments in Asia-Pacific, mark...
The CDC has extended its travel ban on individuals from Uganda, South Sudan, and the DRC to include green card holders, raising concerns among healthc...
NanoViricides announces its broad-spectrum antiviral NV-387 may be evaluated for the Bundibugyo Ebola outbreak, as no approved therapies exist for thi...
NanoViricides emphasizes the potential of its broad-spectrum antiviral candidate NV-387 as a pandemic preparedness tool during the ongoing Bundibugyo ...
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
Ongoing conflict in Iran is straining the supply of essential processing chemicals for cobalt and copper miners in the Democratic Republic of Congo, l...
NanoViricides announced the imminent start of a Phase II trial for NV-387 against MPox in the Democratic Republic of Congo, advancing a potential trea...
Virtus Minerals, a US-based critical minerals firm, will acquire Chemaf, a DRC miner of lithium and cobalt, highlighting the strategic importance of s...
Easy Environmental Solutions gains momentum in early 2026 with increased production and new trials for its Terreplenish microbial solution, capitalizi...
NanoViricides announced completion of manufacturing for its NV-387 Oral Gummies drug product for a Phase II monkeypox trial and will present its broad...
The Democratic Republic of Congo has ended its 10-month ban on cobalt exports, underscoring the risks of concentrated supply chains for critical miner...
Micropolis AI Robotics signs a $9.3 million development and distribution agreement with AfricAI to create customized unmanned ground vehicles for Afri...
NanoViricides' lead drug candidate NV-387 shows promise as a broad-spectrum antiviral with completed Phase I safety data and readiness for Phase II MP...
The Democratic Republic of Congo's suspension of cobalt exports and shift to a quota system threatens to create a global deficit by 2026, impacting su...
